target,target_id,target_uniprot,target_species,ligand,ligand_id,ligand_species,ligand_pubchem_cid,smiles,inchi,inchikey,type,action,action_comment,endogenous,primary_target,concentration_range,affinity_parameter,affinity_high,affinity_median,affinity_low,original_affinity_units,original_affinity_low_nm,original_affinity_median_nm,original_affinity_high_nm,original_affinity_relation,assay_description,receptor_site,ligand_context,pubmed_id proprotein convertase subtilisin/kexin type 9,2388,Q8NBP7,Human,alirocumab,6744,,,,,,Antibody,Binding,,,yes,,pKd,,9.42,,Kd,,0.377,,=,,,,, proprotein convertase subtilisin/kexin type 9,2388,Q8NBP7,Human,evolocumab,7343,,,,,,Antibody,Binding,,,yes,,pKd,,9.72,,Kd,,0.19,,=,"Dissociation equilibrium constant for wild-type hPCSK9, measured using proprietary BIACore® technology.",,,, proprotein convertase subtilisin/kexin type 9,2388,Q8NBP7,Human,bococizumab,7730,,,,,,Antibody,Binding,,,yes,,pKd,,10.0,,Kd,,0.1,,=,Affinity for hPCSK9 measured using proprietary BIACore® technology.,,,, proprotein convertase subtilisin/kexin type 9,2388,Q8NBP7,Human,compound 16 [PMID: 31653597],10713,,139592542,CC(OC(=O)N[C@H](C(=O)NCCOCCOc1cc2CCN[C@](c2cc1Oc1ccc(c(c1)F)c1ccc(cc1)C(=O)O)(C)CC(=O)Nc1nccs1)CCCN/C(=N/C(=O)OC(C)(C)C)/NC(=O)OC(C)(C)C)(C)C,"InChI=1S/C53H69FN8O13S/c1-50(2,3)73-47(67)59-39(12-11-20-56-45(61-48(68)74-51(4,5)6)62-49(69)75-52(7,8)9)43(64)55-22-24-70-25-26-71-40-28-34-19-21-58-53(10,31-42(63)60-46-57-23-27-76-46)37(34)30-41(40)72-35-17-18-36(38(54)29-35)32-13-15-33(16-14-32)44(65)66/h13-18,23,27-30,39,58H,11-12,19-22,24-26,31H2,1-10H3,(H,55,64)(H,59,67)(H,65,66)(H,57,60,63)(H2,56,61,62,68,69)/t39-,53+/m0/s1",BOAJXEFAPWTSFX-FXASYPJLSA-N,None,Binding,,,,,pKi,,6.97,,Ki,,107.0,,=,Determined in a fluorescence polarization assay.,,,31653597, proprotein convertase subtilisin/kexin type 9,2388,Q8NBP7,Human,"SBC-115,337",11539,,1369939,O=C(c1ccc(cc1)NC(=O)c1oc2c(c1)cccc2)Nc1ccc(cc1)c1oc2c(n1)cccc2,"InChI=1S/C29H19N3O4/c33-27(30-21-15-11-19(12-16-21)29-32-23-6-2-4-8-25(23)36-29)18-9-13-22(14-10-18)31-28(34)26-17-20-5-1-3-7-24(20)35-26/h1-17H,(H,30,33)(H,31,34)",ALQIZRCPSILFNQ-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,6.3,,6.22,IC50,600.0,,500.0,=,Inhibition of the PCSK9/ LDLR interaction in an ELISA,,,, proprotein convertase subtilisin/kexin type 9,2388,Q8NBP7,Human,tafolecimab,12517,,,,,,Antibody,Binding,,,,,,,,,,,,,=,,,,, proprotein convertase subtilisin/kexin type 9,2388,Q8NBP7,Human,MK-0616,12689,,167312471,CC1=CC(=CC(=C1)N2C=C(N=N2)CN3C=C(C4=C3C=CC(=C4)F)C[C@H]5C(=O)N6CC[C@@H]([C@H]6C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC7=CC=C(C=C7)OC)C(=O)N8CCC[C@@]8(C)C(=O)NCCS)OC/C=C/CC9=CC(=CC=C9)C[C@@H](C(=O)N5)NC(=O)[C@@H](C)NC(=O)[C@H](CNC(=O)CCOCCOCC[N+](C)(C)C)NC(=O)CCS)C,"InChI=1S/C81H108FN15O15S2/c1-50-38-51(2)40-60(39-50)96-49-59(91-92-96)48-93-47-57(62-45-58(82)19-22-67(62)93)44-65-78(106)94-29-23-68(72(94)77(105)90-71(53(4)98)76(104)89-64(42-55-17-20-61(109-9)21-18-55)79(107)95-28-13-26-81(95,5)80(108)83-27-37-114)112-31-11-10-14-54-15-12-16-56(41-54)43-63(74(102)88-65)87-73(101)52(3)85-75(103)66(86-70(100)25-36-113)46-84-69(99)24-32-110-34-35-111-33-30-97(6,7)8/h10-12,15-22,38-41,45,47,49,52-53,63-66,68,71-72,98H,13-14,23-37,42-44,46,48H2,1-9H3,(H9-,83,84,85,86,87,88,89,90,99,100,101,102,103,104,105,108,113,114)/p+1/b11-10+/t52-,53-,63+,64+,65+,66+,68+,71+,72+,81+/m1/s1",WQYKXIAUKXSSIN-ZPWCAMBLSA-O,Inhibitor,Binding,,,,,pKi,,11.3,,Ki,,0.005,,=,Binding affinity for hPCSK9 determined in a TR-FRET assay,,,37125593,